Standardized uptake value

Last updated February 28, 2024

3-dimensional [ F]FDG-PET image with 3D ROI generated by a threshold based algorithm. The blue dot in the MIP image bottom right marks the maximum SUV within the ROI. 3D-PET-SUV.jpg — 3-dimensional [ F]FDG-PET image with 3D ROI generated by a threshold based algorithm. The blue dot in the MIP image bottom right marks the maximum SUV within the ROI.

The standardized uptake value (SUV) is a nuclear medicine term, used in positron emission tomography (PET) as well as in modern calibrated single photon emission tomography (SPECT) imaging for a semiquantitative analysis.^[1] Its use is particularly common in the analysis of [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) images of cancer patients. It can also be used with other PET agents especially when no arterial input function is available for more detailed pharmacokinetic modeling. Otherwise measures like the fractional uptake rate (FUR) or parameters from more advanced pharmacokinetic modeling may be preferable.

Discussion

While this equation looks simple, there are a number of points that need to be discussed, such as (1) the origin of c_img data, (2) the origin of c_inj data, (3) time, and (4) units.

Image

The c_img data may be the pixel intensities of a calibrated PET image. Calculated SUV data can then be visualized as parametric SUV image. Alternatively, groups of such pixels may be selected e.g. by manually drawing or otherwise segmenting a region of interest (ROI) on the PET image. Then e.g. the average intensity of that ROI may be used as c_img input to calculate SUV values.

Injection

The c_inj value is calculated as ratio of two independent measurements: the injected radioactivity (injected dose, ID) and the body weight (BW) of the subject. The ID can be estimated e.g. as difference in the radioactivity of the syringe before and after injection, if deemed necessary with correction for physical decay between each of those measurements and the time of injection. Conventionally the time of injection is t=0. This reference concentration represents the hypothetical case of an even distribution of the injected radioactivity across the whole body. Measured SUV values in particular parts of the body thus quantify the deviation from this hypothetical even radioactivity distribution: SUV> 1 indicates radioactivity accumulation in that region above the hypothetical even radioactivity distribution.

Time (Physical Decay)

The injection of radioactivity is often followed by a waiting time interval and then a time span during which the PET image data are acquired. After image reconstruction, the image c_img (t) data need to be decay corrected to the injection time point t=0. The time point t may be the image acquisition start time, or in case of a long acquisition duration e.g. the midpoint of the PET image acquisition may be more appropriate. This decay correction needs to be done for each image in case of a series of images acquired after a single injection ("dynamic imaging").

Mass and Volume

The unit of c_img is MBq/mL or equivalent, based on (a) the pixel intensity calibrated with a radioactive source ("phantom") itself of known radioactivity and volume, and (b) the pixel volume or ROI volume. The unit of c_inj is MBq/g or equivalent, based on the measured radioactivity and the subject's body weight. This would give SUV in units of g/mL or equivalent. However, SUV is typically presented as a unitless parameter. One way to explain this simplification is by considering that the average mass density of the human body is typically close to 1 g/mL. Thus, while the body weight is usually measured and used for the SUV calculation, this is implicitly converted to the body volume in mL by division by 1 g/mL resulting in a unitless SUV parameter.

Alternatively, the c_img may be considered implicitly converted into a mass concentration assuming a mass density of 1 g/mL for the ROI volume which is a good approximation for some but not all tissues in the human body.

Equation

In summary this gives the following equation to calculate SUV at time t post injection,

$SUV(t)={\frac {c_{img}(t)}{ID/BW}}$ ^[3]

with (1) the radioactivity measured from an image acquired at (or around) the time t, decay corrected to t=0 and expressed as volume concentration (e.g. MBq/mL), (2) the injected dose ID at t=0 (e.g. in MBq), and (3) the body weight BW (near the time of image acquisition) implicitly converted into the body volume assuming an average mass density of 1 g/mL.

A related measure more frequently used in preclinical PET and SPECT is the concentration in units of % ID/mL (percentage of the injected dose per mL of tissue) for biodistribution analysis. When obtained from radionuclear images, this is equal to

$\%ID/mL(t)={\frac {c_{img}(t)}{ID}}\cdot 100\%$ .

In other words, SUV can be interpreted as the % ID/mL normalized to (here, multiplied by) the body weight (or body volume) and expressed as fraction rather than percentage.

Further Considerations

Some authors replace the body weight by the lean body weight ^[4] or the body surface area.^[5]

Also for $c(t)$ from a region of interest, different measures are found in the literature, e.g., the maximum intensity value within the ROI, the mean intensity value of the ROI,^[6] or the mean intensity value of the ROI after applying an intensity threshold (thus excluding a number of pixels of the ROI).

Accuracy and Precision

The SUV can be significantly affected among other things by image noise, low image resolution and/or user biased ROI selection.^[7] For the semiquantitative analysis of [¹⁸F]FDG uptake in tissue or tumor, several corrections have been recommended (see ^[8] and references therein).

SUVR

The ratio of the SUV data from two different regions within the same PET image (i.e. from a target and a reference region) is commonly abbreviated SUVR. An example is the ratio of regional Pittsburgh compound B PET signal intensity to the average signal of a much wider region.^[9] For the SUVR, the injected activity, the body weight and the mass density that are all part of the SUV calculation, cancel:

${\mathit {SUVR}}={\frac {\mathit {SUV_{target}}}{\mathit {SUV_{reference}}}}={\frac {\mathit {c_{img,target}}}{\mathit {c_{img,reference}}}}.$

Outlook and Conclusions

As of 2007, the SUV concept had only begun to be tested for other radiotracers such as fluorothymidine F-18 ([¹⁸F]FLT) and conclusions on its usefulness and robustness in these cases were considered premature then.^[10]

In summary, the SUV is a convenient measure for the comparison of [¹⁸F]FDG PET images from subjects with different body masses. However, care has to be taken with respect to its pitfalls and with respect to the interpretation of results.

Related Research Articles

<span class="mw-page-title-main">Positron emission tomography</span> Medical imaging technique

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.

Nuclear medicine or nucleology is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging, in a sense, is "radiology done inside out" because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

<span class="mw-page-title-main">Vasculitis</span> Medical disorders that destroy blood vessels by inflammation

Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both arteries and veins are affected. Lymphangitis is sometimes considered a type of vasculitis. Vasculitis is primarily caused by leukocyte migration and resultant damage. Although both occur in vasculitis, inflammation of veins (phlebitis) or arteries (arteritis) on their own are separate entities.

Radionuclide angiography is an area of nuclear medicine which specialises in imaging to show the functionality of the right and left ventricles of the heart, thus allowing informed diagnostic intervention in heart failure. It involves use of a radiopharmaceutical, injected into a patient, and a gamma camera for acquisition. A MUGA scan involves an acquisition triggered (gated) at different points of the cardiac cycle. MUGA scanning is also called equilibrium radionuclide angiocardiography, radionuclide ventriculography (RNVG), or gated blood pool imaging, as well as SYMA scanning.

A bone scan or bone scintigraphy is a nuclear medicine imaging technique of the bone. It can help diagnose a number of bone conditions, including cancer of the bone or metastasis, location of bone inflammation and fractures, and bone infection (osteomyelitis).

[¹⁸F]Fluorodeoxyglucose (INN), or fluorodeoxyglucose F 18, also commonly called fluorodeoxyglucose and abbreviated [¹⁸F]FDG, 2-[¹⁸F]FDG or FDG, is a radiopharmaceutical, specifically a radiotracer, used in the medical imaging modality positron emission tomography (PET). Chemically, it is 2-deoxy-2-[¹⁸F]fluoro-D-glucose, a glucose analog, with the positron-emitting radionuclide fluorine-18 substituted for the normal hydroxyl group at the C-2 position in the glucose molecule.

Ioflupane (¹²³I) is the international nonproprietary name (INN) of a cocaine analogue which is a neuro-imaging radiopharmaceutical drug, used in nuclear medicine for the diagnosis of Parkinson's disease and the differential diagnosis of Parkinson's disease over other disorders presenting similar symptoms. During the DaT scan procedure it is injected into a patient and viewed with a gamma camera in order to acquire SPECT images of the brain with particular respect to the striatum, a subcortical region of the basal ganglia. The drug is sold under the brand name Datscan and is manufactured by GE Healthcare, formerly Amersham plc.

Positron emission tomography–computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed (co-registered) image. Thus, functional imaging obtained by PET, which depicts the spatial distribution of metabolic or biochemical activity in the body can be more precisely aligned or correlated with anatomic imaging obtained by CT scanning. Two- and three-dimensional image reconstruction may be rendered as a function of a common software and control system.

Rubidium-82 (⁸²Rb) is a radioactive isotope of rubidium. ⁸²Rb is widely used in myocardial perfusion imaging. This isotope undergoes rapid uptake by myocardiocytes, which makes it a valuable tool for identifying myocardial ischemia in Positron Emission Tomography (PET) imaging. ⁸²Rb is used in the pharmaceutical industry and is marketed as Rubidium-82 chloride under the trade names RUBY-FILL and CardioGen-82.

Brain positron emission tomography is a form of positron emission tomography (PET) that is used to measure brain metabolism and the distribution of exogenous radiolabeled chemical agents throughout the brain. PET measures emissions from radioactively labeled metabolically active chemicals that have been injected into the bloodstream. The emission data from brain PET are computer-processed to produce multi-dimensional images of the distribution of the chemicals throughout the brain.

Positron emission mammography (PEM) is a nuclear medicine imaging modality used to detect or characterise breast cancer. Mammography typically refers to x-ray imaging of the breast, while PEM uses an injected positron emitting isotope and a dedicated scanner to locate breast tumors. Scintimammography is another nuclear medicine breast imaging technique, however it is performed using a gamma camera. Breasts can be imaged on standard whole-body PET scanners, however dedicated PEM scanners offer advantages including improved resolution.

Mefway is a serotonin 5-HT_1A receptor antagonist used in medical research, usually in the form of mefway (¹⁸F) as a positron emission tomography (PET) radiotracer.

Florbetaben, a fluorine-18 (18F)-labeled stilbene derivative, trade name NeuraCeq, is a diagnostic radiotracer developed for routine clinical application to visualize β-amyloid plaques in the brain. It is indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. β-amyloid is a key neuropathological hallmark of AD, so markers of β-amyloid plaque accumulation in the brain are useful in distinguishing AD from other causes of dementia. The tracer successfully completed a global multicenter phase 0–III development program and obtained approval in Europe, US and South Korea in 2014.

Metabolic trapping refers to a localization mechanism of synthesized radiocompounds in the human body. It can be defined as the intracellular accumulation of a radioactive tracer based on the relative metabolic activity of the body's tissues. It is a basic principle of the design of radiopharmaceuticals as metabolic probes for functional studies or tumor location.

Fluciclovine (¹⁸F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, or as Axumin, is a diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels.

<span class="mw-page-title-main">Siroos Mirzaei</span> Iranian specialist in Nuclear Medicine (born 1963)

Siroos Mirzaei is an Iranian specialist in Nuclear Medicine. He is Head of the Department of Nuclear Medicine of the Wilhelminen Hospital in Vienna. Mirzaei is well known for his scientific work on torture diagnostics with molecular imaging methods.

Carbon-11 choline is the basis of medical imaging technologies. Because of its involvement in biologic processes, choline is related to diseases, leading to the development of medical imaging techniques to monitor its concentration. When radiolabeled with ¹¹CH₃, choline is a useful a tracer in PET imaging. Carbon-11 is radioactive with a half-life of 20.38 minutes. By monitoring the gamma radiation resulting from the decay of carbon-11, the uptake, distribution, and retention of carbon-11 choline can be monitored.

Arterial input function (AIF), also known as a plasma input function, refers to the concentration of tracer in blood-plasma in an artery measured over time. The oldest record on PubMed shows that AIF was used by Harvey et al. in 1962 to measure the exchange of materials between red blood cells and blood plasma, and by other researchers in 1983 for positron emission tomography (PET) studies. Nowadays, kinetic analysis is performed in various medical imaging techniques, which requires an AIF as one of the inputs to the mathematical model, for example, in dynamic PET imaging, or perfusion CT, or dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

In medical imaging, a time-activity curve is a curve of radioactivity plotted on the y-axis against the time plotted on the x-axis. It shows the concentration of a radiotracer within a region of interest in an image, measured over time from a dynamic scan. Generally, when a time-activity curve is obtained within a tissue, it is called as a tissue time-activity curve, which represents the concentration of tracer within a region of interest inside a tissue over time.

Positron emission tomography for bone imaging, as an in vivo tracer technique, allows the measurement of the regional concentration of radioactivity proportional to the image pixel values averaged over a region of interest (ROI) in bones. Positron emission tomography is a functional imaging technique that uses [¹⁸F]NaF radiotracer to visualise and quantify regional bone metabolism and blood flow. [¹⁸F]NaF has been used for imaging bones for the last 60 years. This article focuses on the pharmacokinetics of [¹⁸F]NaF in bones, and various semi-quantitative and quantitative methods for quantifying regional bone metabolism using [¹⁸F]NaF PET images.

References

↑ G. Lucignani; G. Paganelli; E. Bombardieri (2004). "The use of standardized uptake values for assessing FDG uptake with PET in oncology: A clinical perspective". Nuclear Medicine Communications. 25 (7): 651–656. doi:10.1097/01.mnm.0000134329.30912.49. PMID 15208491. S2CID 38728335.
↑ Mah, Katherine; Caldwell, Curtis B. (2008-01-01), Paulino, Arnold C.; Teh, Bin S. (eds.), "chapter 4 - Biological Target Volume", PET-CT in Radiotherapy Treatment Planning, Philadelphia: Elsevier, pp. 52–89, ISBN 978-1-4160-3224-3 , retrieved 2023-11-17
↑ Ziessman, Harvey A.; O'Malley, Janis P.; Thrall, James H., eds. (2014-01-01), "Chapter 11 - Oncology: Positron Emission Tomography", Nuclear Medicine (Fourth Edition), Philadelphia: W.B. Saunders, pp. 227–264, doi:10.1016/B978-0-323-08299-0.00011-0, ISBN 978-0-323-08299-0 , retrieved 2023-11-17
↑ K. R. Zasadny; R. L. Wahl (1993). "Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction". Radiology. 189 (3): 847–850. doi:10.1148/radiology.189.3.8234714. PMID 8234714.
↑ C. K. Kim; N. C. Gupta; B. Chandramouli; A. Alavi (1994). "Standardized uptake values of FDG: body surface area correction is preferable to body weight correction". Journal of Nuclear Medicine. 35 (1): 164–167. PMID 8271040.
↑ Vesa Oikonen. "Standardized uptake rate (SUV)" . Retrieved 2009-07-22.
↑ R. Boellaard; N. C. Krak; O. S. Hoekstra; A. A. Lammertsma (2004). "Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study". Journal of Nuclear Medicine. 45 (9): 1519–1527. PMID 15347719.
↑ S.-C. Huang (2000). "Anatomy of SUV". Nuclear Medicine and Biology. 27 (7): 643–646. doi:10.1016/s0969-8051(00)00155-4. PMID 11091106.
↑ Zhou L1, Salvado O2, Dore V2, Bourgeat P2, Raniga P2, Macaulay SL3, Ames D4, Masters CL5, Ellis KA6, Villemagne VL7, Rowe CC7, Fripp J2; AIBL Research Group (2014). "MR-less surface-based amyloid assessment based on 11C PiB PET". PLOS ONE . 9 (1): e84777. Bibcode:2014PLoSO...984777Z. doi: 10.1371/journal.pone.0084777 . PMC 3888418 . PMID 24427295.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
↑ R. J. Hicks (2007). "The SUV and FLT PET: A tasty alphabet soup or a dog's breakfast?". Leukemia & Lymphoma. 48 (4): 649–652. doi:10.1080/10428190701262059. PMID 17454619. S2CID 44826569.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] G. Lucignani; G. Paganelli; E. Bombardieri (2004). "The use of standardized uptake values for assessing FDG uptake with PET in oncology: A clinical perspective". Nuclear Medicine Communications. 25 (7): 651–656. doi:10.1097/01.mnm.0000134329.30912.49. PMID 15208491. S2CID 38728335.

[2] Mah, Katherine; Caldwell, Curtis B. (2008-01-01), Paulino, Arnold C.; Teh, Bin S. (eds.), "chapter 4 - Biological Target Volume", PET-CT in Radiotherapy Treatment Planning, Philadelphia: Elsevier, pp. 52–89, ISBN 978-1-4160-3224-3 , retrieved 2023-11-17

[3] Ziessman, Harvey A.; O'Malley, Janis P.; Thrall, James H., eds. (2014-01-01), "Chapter 11 - Oncology: Positron Emission Tomography", Nuclear Medicine (Fourth Edition), Philadelphia: W.B. Saunders, pp. 227–264, doi:10.1016/B978-0-323-08299-0.00011-0, ISBN 978-0-323-08299-0 , retrieved 2023-11-17

[4] K. R. Zasadny; R. L. Wahl (1993). "Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction". Radiology. 189 (3): 847–850. doi:10.1148/radiology.189.3.8234714. PMID 8234714.

[5] C. K. Kim; N. C. Gupta; B. Chandramouli; A. Alavi (1994). "Standardized uptake values of FDG: body surface area correction is preferable to body weight correction". Journal of Nuclear Medicine. 35 (1): 164–167. PMID 8271040.

[6] Vesa Oikonen. "Standardized uptake rate (SUV)" . Retrieved 2009-07-22.

[7] R. Boellaard; N. C. Krak; O. S. Hoekstra; A. A. Lammertsma (2004). "Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study". Journal of Nuclear Medicine. 45 (9): 1519–1527. PMID 15347719.

[8] S.-C. Huang (2000). "Anatomy of SUV". Nuclear Medicine and Biology. 27 (7): 643–646. doi:10.1016/s0969-8051(00)00155-4. PMID 11091106.

[pmid24427295-9] Zhou L1, Salvado O2, Dore V2, Bourgeat P2, Raniga P2, Macaulay SL3, Ames D4, Masters CL5, Ellis KA6, Villemagne VL7, Rowe CC7, Fripp J2; AIBL Research Group (2014). "MR-less surface-based amyloid assessment based on 11C PiB PET". PLOS ONE . 9 (1): e84777. Bibcode:2014PLoSO...984777Z. doi: 10.1371/journal.pone.0084777 . PMC 3888418 . PMID 24427295.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)

[10] R. J. Hicks (2007). "The SUV and FLT PET: A tasty alphabet soup or a dog's breakfast?". Leukemia & Lymphoma. 48 (4): 649–652. doi:10.1080/10428190701262059. PMID 17454619. S2CID 44826569.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]